• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Spherix Global Insights

    < Previous 1 2 3 4 Next >
    US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
    From Spherix Global Insights
    Via GlobeNewswire
    Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
    From Spherix Global Insights
    Via GlobeNewswire
    US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
    From Spherix Global Insights
    Via GlobeNewswire
    IgA Nephropathy Pipeline Dynamics Signal Further Treatment Evolution on the Horizon
    From Spherix Global Insights
    Via GlobeNewswire
    How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
    From Spherix Global Insights
    Via GlobeNewswire
    Charting New Paths: Non-TNF's Evolving in Rheumatoid Arthritis Market
    From Spherix Global Insights
    Via GlobeNewswire
    Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
    From Spherix Global Insights
    Via GlobeNewswire
    Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
    From Spherix Global Insights
    Via GlobeNewswire
    Stakes Are High for Regeneron's Eylea HD as Genentech's Vabysmo Continues to Gain Momentum, Prompting Doctors to Weigh Their Options Between Two Industry Titans, According to Spherix Global Insights
    From Spherix Global Insights
    Via GlobeNewswire
    Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors
    From Spherix Global Insights
    Via GlobeNewswire
    Spherix Global Insights Delivers Cheeriodicals to Dialysis Patients
    From Spherix Global Insights
    Via GlobeNewswire
    Novartis' Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie's Humira
    From Spherix Global Insights
    Via GlobeNewswire
    Use of SGLT2 Inhibitors Continues to Expand for the Treatment of Chronic Kidney Disease, with Eli Lilly/Boehringer Ingelheim’s Jardiance Making Significant Strides Following Label Expansion
    From Spherix Global Insights
    Via GlobeNewswire
    US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
    From Spherix Global Insights
    Via GlobeNewswire
    “I Need to See It With My Own Eyes”: How US Ophthalmologists React to Apellis’ Syfovre Safety Warnings When Managing Geographic Atrophy
    From Spherix Global Insights
    Via GlobeNewswire
    U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
    From Spherix Global Insights
    Via GlobeNewswire
    FibroGen/Astellas’ EVRENZO (roxadustat) Making In-Roads in European Market as In-Class Challenger, Akebia/Medice’s VAFSEO (vadadustat), Prepares for Launch in Early 2024.
    From Spherix Global Insights
    Via GlobeNewswire
    BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
    From Spherix Global Insights
    Via GlobeNewswire
    When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
    From Spherix Global Insights
    Via GlobeNewswire
    Eli Lilly's Olumiant and Pfizer's Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
    From Spherix Global Insights
    Via GlobeNewswire
    US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lilly's Omvoh, Pfizer's Velsipity, Takeda's Subcutaneous Entyvio, and Celltrion's Zymfentra
    From Spherix Global Insights
    Via GlobeNewswire
    Spherix Global Insights Amplifies the Lupus Patient Voice, Highlighting the Lengthy and Challenging Journey to Diagnosis and Treatment
    From Spherix Global Insights
    Via GlobeNewswire
    US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights
    From Spherix Global Insights
    Via GlobeNewswire
    Rate of Switching from Regeneron’s Eylea to Genentech’s Vabysmo Doubled Over Past Year for Diabetic Macular Edema
    From Spherix Global Insights
    Via GlobeNewswire
    US Nephrologists Embrace Current IgA Nephropathy Therapies, Yet a Thriving Pipeline Signals Fierce Market Evolution Ahead
    From Spherix Global Insights
    Via GlobeNewswire
    In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global In
    From Spherix Global Insights
    Via GlobeNewswire
    Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
    From Spherix Global Insights
    Via GlobeNewswire
    Spherix Introduces Patient Chart Dynamix™, an Enhanced Independent Pharmaceutical Market Research Chart Audit
    From Spherix Global Insights
    Via GlobeNewswire
    Spherix Global Insights Announces New Leadership to Drive Growth and Innovation
    From Spherix Global Insights
    Via GlobeNewswire
    Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
    From Spherix Global Insights
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.